Infliximab versus cyclosporine treatment for severe corticosteroid-refractory ulcerative colitis: A Korean, retrospective, single center study

Gut and Liver

Volumn 9, Issue 5, 2015, Pages 601-606

  Kim, Eun Hye ^a   Kim, Duk Hwan ^a   Park, Soo Jung ^a   Hong, Sung Pil ^a   Kim, Tae Il ^a   Kim, Won Ho ^a   Cheon, Jae Hee ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Colitis, ulcerative; Cyclosporine; Infliximab

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN; HYDROCORTISONE; INFLIXIMAB; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON RESECTION; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID REFRACTORY ULCERATIVE COLITIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KOREA; MALE; MEDICAL RECORD REVIEW; PANCYTOPENIA; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; MIDDLE AGED; PROCEDURES; PROPORTIONAL HAZARDS MODEL; SALVAGE THERAPY; SOUTH KOREA; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; YOUNG ADULT;

ADRENAL CORTEX HORMONES; ADULT; AGED; AZATHIOPRINE; COLECTOMY; COLITIS, ULCERATIVE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942105035     PISSN: 19762283     EISSN: 20051212     Source Type: Journal    
DOI: 10.5009/gnl14120     Document Type: Article

References (35)

1. Gracie DJ, Ford AC. Evidence-based management of ulcerative colitis. Minerva Gastroenterol Dietol 2012;58:87-99.
2. Dean KE, Hikaka J, Huakau JT, Walmsley RS. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. J Gastroenterol Hepatol 2012;27:487-492.
3. Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010;4:431-437.
4. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955;2:1041-1048.
5. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067-1070.
6. Kim DH, Cheon JH, Park JJ, et al. Clinical outcomes and predictive factors for response after the first course of corticosteroid therapy in patients with Crohn's disease. Gut Liver 2013;7:58-65.
7. Gearry RB, Falvey JD. Rescue therapy for steroid refractory acute severe ulcerative colitis: more choice, better outcomes? J Gastroenterol Hepatol 2012;27:417-418.
8. Kaur M, Targan SR. Ulcerative colitis: steroid-refractory ulcerative colitis-ciclosporin or infliximab? Nat Rev Gastroenterol Hepatol 2013;10:8-9.
9. Järnerot G, Rolny P, Sandberg-Gertzén H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-1013.
10. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-1845.
11. Levesque BG, Sandborn WJ. Infliximab versus ciclosporin in severe ulcerative colitis. Lancet 2012;380:1887-1888.
12. Rolny P, Vatn M. Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab: review article. Scand J Gastroenterol 2013;48:131-135.
13. Singh S, Loftus EV Jr. Management of severe steroid-refractory ulcerative colitis: cyclosporine or infliximab? Gastroenterology 2013;144:1138-1140.
14. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004;10:73-78.
15. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.
16. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-1811.
17. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012;380:1909-1915.
18. Lee KM, Jeen YT, Cho JY, et al. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. J Gastroenterol Hepatol 2013;28:1829-1833.
19. González-Altamirano J, Paz-Delgadillo J, Bosques-Padilla F. Advances in the diagnosis, pathophysiology and treatment of chronic non-specific ulcerative colitis. Rev Gastroenterol Mex 2013;78 Suppl 1:65-67.
20. Mocciaro F, Renna S, Orlando A, et al. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study. J Crohns Colitis 2012;6:681-686.
21. Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver 2010;4:1-14.
22. Lee JH, Cheon JH, Kim ES, et al. The prevalence and clinical significance of perinuclear anti-neutrophil cytoplasmic antibody in Korean patients with ulcerative colitis. Dig Dis Sci 2010;55:1406-1412.
23. Lee JH, Cheon JH, Moon CM, et al. Do patients with ulcerative colitis diagnosed at a young age have more severe disease activity than patients diagnosed when older? Digestion 2010;81:237-243.
24. Lee HJ, Jung ES, Lee JH, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis. Hepatogastroenterology 2012;59:1415-1420.
25. Chung GE, Cheon JH, Lee JY, et al. Efficacy of combination of intravenous cyclosporin A and steroid therapy versus prolonged intravenous steroid therapy alone in patients with severe ulcerative colitis refractory to initial intravenous steroid therapy. Korean J Gastroenterol 2006;48:263-268.
26. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999;94:1587-1592.
27. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-1262.
28. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroidrefractory or steroid-dependent inflammatory bowel disease: a long-term follow-up. Am J Gastroenterol 2006;101:1048-1056.
29. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006;4:760-765.
30. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7:83-88.
31. Travis S, Satsangi J, Lémann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut 2011;60:3-9.
32. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-1260.
33. Farkas K, Lakatos PL, Nagy F, et al. Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scand J Gastroenterol 2013;48:1394-1398.
34. Löwenberg M, De Boer NK, Dewint P, Hoentjen F. Treatment of patients with severe glucocorticoid-refractory ulcerative colitis: cyclosporine or infliximab? Ned Tijdschr Geneeskd 2013;157:A6130.
35. Croft A, Walsh A, Doecke J, Cooley R, Howlett M, Radford-Smith G. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther 2013;38:294-302.